Pharmacology

caffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasoundcaffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasound

caffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasoundcaffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasound

caffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasoundcaffeine, brachial endothelial function, coronary artery disease, Sheba Medical Center, high-sensitivity C-reactive protein, hs-CRP, serum adiponectin, brachial artery flow-mediated dilated, FMD, nitroglycerin-mediated dilation, NTG, high-resolution ultrasound

corticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFAcorticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFA

corticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFAcorticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFA

corticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFAcorticosteroids, mortality rates, community-acquired pneumonia, CAP, Barra D'Or Hospital, Garcia de Ortz Hospital, bronchospasm, septic shock, C-reactive protein, CRP, chronic obstructive pulmonary disease, Acute Physiology and Chronic Health Evaluation II, APACHE, Sequential Organ Failure Assessment, SOFA

nonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertensionnonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertension

nonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertensionnonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertension

nonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertensionnonsteroidal anti-inflammatory drugs, NSAIDs, osteoarthritis, increased blood pressure, BP, naproxcinod, naproxen, renin-angiotensin system inhibitors, RAS, vascular disease, hypertension

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia